References

1. Felson, DT, Lawrence, RC, Dieppte, PA, Hirsch, R, Helmick, CG, Jordan, JM, Kington, RS, Lane, NE, Nevitt, MC, Zhang, Y, Sowers, M, McAlindon, T, Spector, TD, Poole, AR, Yanovski, SZ, Ateshian, G, Sharma, L, Buckwalter, JA, Brandt, KD, Fries, JF. 2000a. Osteoarthritis: New Insights: Part 1: The Disease and Its Risk Factors. Ann Intern Med, 133(8): 635-646.
2. Martel-Pelletier, J, Lajeunesse, D, Reboul, P, Pelletier, JP. 2003. Therapeutic Role of Dual Inhibitors of 5-LOX and COX, Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs. Ann. Rhem. Dis, 62:501-09.
3. Hardy, MM, Seibert, K, Manning, PT, Currie, MG, Woerner, BM, Edwards, D, Koki, A, Tripp, CS. 2002. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 46: 1789-803.
4. Steiner, DR, Gonzalez, NC, Wood, JG. 2001. Leukotriene B4 promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J Appl Physiol, 91: 1160–1167.
5. Martel-Pelletier J, Mineau F, Fahmi H, Laufer S, Reboul P, Boileau C, Lavigne M, Pelletier JP. 2004. Regulation of the expression of 5-lipoxygenase-activating protein-5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthrits Rheum. 50(12):3925-33; Marcouiller P, Pelletier JP, Guevremont M, Martel-Pelletier J, Ranger P, Laufer S, Reboul P. 2005. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membrane: regulating factors for interleukin 1beta synthesis. J. Rheumatol. 32(4):704-12.
6. Aspden, RM, Scheven, BAA, Hutchison, JD. 2001. Osteoarthritis is a systemic disorder involving stromal cell differentiation and lipid metabolism. Lancet. 357:1118-1120.
7. Bonizzi, G, Piette, J, Schoonbroodt, S, Greimers, R, Harvard, L, Merville, MP, Bours, V. 1999. Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol. Cell. Biol. 19:1950-60.
8. Konig, W., W. Schonfeld, M. Raulf, M. Koeller, J. Kneller, J. Scheffer, and J. Brom. 1990. The neutrophil and leukotrienes-role in health and disease. Eicosanoids. 3:1-22.
9. Hudson, N, Balsitis, M, Everitt, S, Hawkey, CJ. 1993. Enhanced Gastric Mucosal Leukotriene B4 Synthesis in Patients Taking Non-steroidal Anti-Inflammatory Drugs. Gut, 34:742-7.
10. Laufer S. 2001. Discovery and development of ML3000. Inflammopharmacology. 9(1-2):101-112.
11. Goetzl EJ, An S, Smith WL. 1995. Specfficity of expression and effects of eicosanoid mediators m normal physiology and human diseases. FASEB J. 9:1051-1058; The Eicosanoids, Ed. Curtis-Prior P, John Wiley & Sons, New York, NY, 2004.
12. Bunting, S, Moncada, S, Vane, JR. 1983. The prostacyclin—thromboxane A2 balance: pathophysiological and theraputic implications. Br. Med. Bull. 39:271-6.
13. Solomon DH. 2005. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum. 52(7):1968-78; Bing, RJ, Lomnicka, M. 2002. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J. Am Coll Cardiol. 39:421.
14. Henrotin YE, Bruckner P, Pujol JP. 2003. The role of reactive oxygen species in homeostatis and degradation of cartilage.Osteoarthritis and Cartilage 2003;11:747-55; Nelson, KK Melendez, JA. 2004. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med. 37(6):768-84.
15. Patton, JS, Shepard, HM, Wilking, H, Lewis, G, Aggarwal, BB, Eessalu, TE, Gavin, LA, Grunfeld, C. 1986. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci USA. 83(21):8313-7.
16. Cao, GH, Alessio, HM, Cutler, RG. 1993. Oxygen-radical absorbency capacity assay for antioxidants. Free Radic Biol Med. 14:303-311.
17. Alt Med Rev 1997; 2(6): 472-480
18. The Japanese Pharmacopoeia, Fourteenth Edition, 2001